Argatroban increases nitric oxide levels in patients with peripheral arterial obstructive disease: Placebo-controlled study

Journal of Thrombosis and Thrombolysis

Volumn 8, Issue 2, 1999, Pages 131-137

  Ueki, Yukitaka ^a   Matsumoto, Kazunari ^a   Kizaki, Yoshihisa ^a   Yoshida, Kazurou ^a   Matsunaga, Yoichi ^a   Yano, Mayumi ^a   Miyake, Seibei ^b   Tominaga, Yuko ^b   Eguchi, Katsumi ^c  

^a SASEBO CHUO HOSPITAL   (Japan)

^b NAGASAKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c NONE

Author keywords

Argatroban; HbNO; Microcirculation; Nitric oxide; PAOD

Indexed keywords

ARGATROBAN; CILOSTAZOL; DIPYRIDAMOLE; HEMOGLOBIN; ICOSAPENTAENOIC ACID; NITRIC OXIDE; PROSTACYCLIN;

ADULT; AGED; ARTICLE; BLOOD LEVEL; CHEMOLUMINESCENCE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LEG; MALE; MICROCIRCULATION; PERIPHERAL CIRCULATION; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THERMOGRAPHY;

AGED; ANTICOAGULANTS; ARTERIAL OCCLUSIVE DISEASES; FEMALE; HEMOGLOBINS; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MICROCIRCULATION; MIDDLE AGED; NITRIC OXIDE; PIPECOLIC ACIDS;

EID: 0032873807     PISSN: 09295305     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008963118789     Document Type: Article

References (35)

1. Kikumoto R, Tamao Y, Tezuka T, et al. Selective inhibition of thrombin by (2R,4R)-4-methyl-1-[N2-[(3-methyl-1,2,3,4- tetrahydro-8-quinolinyl+ + +) sulfonyl]-l-arginyl)]-2-piperidinecarboxylic acid. Biochemistry 1984;23:85-90.
2. Green D, Ts'ao C, Reynolds N, Kahn D, Kohl H, Cohen I. In vitro studies of a new synthetic thrombin inhibitor. Thromb Res 1985;37:145-153.
3. Hara H, Tamao Y, Kikumoto R, Okamoto S. Effect of a synthetic thrombin inhibitor MCI-9038 on experimental models of disseminated intravascular coagulation in rabbits. Thromb Haemost 1987;57:165-170.
4. Jang IK, Gold HK, Ziskind AA, Leinbach RC, Fallon JT, Collen D. Prevention of platelet-rich arterial thrombosis by selective thrombin inhibition. Circulation 1990;81:219-225.
5. Jang IK, Gold HK, Leinbach RC, Fallon JT, Collen D. In vivo thrombin inhibition enhances and sustains arterial recanalization with recombinant tissue-type plasminogen activator. Circ Res 1990;67:1552-1561.
6. Imura Y, Stassen JM, Collen D. Comparative antithrombotic effects of heparin, recombinant hirudin and argatroban in a hamster femoral vein platelet-rich mural thrombosis model. J Pharmacol Exp Ther 1992;261:895-898.
7. Kumon K, Tanaka K, Nakajima N, Naito Y, Fujita T. Anticoagulation with a synthetic thrombin inhibitor after cardiovascular surgery and for treatment of disseminated intravascular coagulation. Crit Care Med 1984;12:1039-1043.
8. Kobayashi S, Kitani M, Yamaguchi S, Suzuki T, Okada K, Tsunematsu T. Effects of an antithrombotic agent (MD-805) on progressing cerebral thrombosis. Thromb Res 1989;53:305-317.
9. Clarke RJ, Mayo G, FitzGerald GA, Fitzgerald DJ. Combined administration of aspirin and a specific thrombin inhibitor in man [see comments]. Circulation 1991;83:1510-1518.
10. Matsuo T, Kario K, Matsuda S, Yamaguchi N, Kakishita E. Effect of thrombin inhibitor on patients with peripheral arterial obstructive disease: A multicenter clinical trial of argatroban. J Thromb Thrombolys 1995;5:131-136.
11. Palmer RM, Ferrige AG, Moncada S. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature 1987;327:524-526.
12. 3 into nitrate is enhanced by endotoxin treatment. Proc Natl Sci USA 1983; 80:4518-4521.
13. Radomski MW, Palmer RM, Moncada S. Endogenous nitric oxide inhibits human platelet adhesion to vascular endothelium. Lancet 1987;2:1057-1058.
14. Hibbs JJ, Taintor RR, Vavrin Z, Rachlin EM. Nitric oxide; A cytotoxic activated macrophage effector molecule. Biochem Biophys Res Commun 1988;157:87-94 [published erratum appears in Biochem Biophys Res Commun 1989;158:624].
15. Lancaster JJ. Simulation of the diffusion and reaction of endogenously produced nitric oxide. Proc Natl Acad Sci USA 1994;91:8137-8141.
16. Wennmalm A, Benthin G, Edlund A, et al. Metabolism and excretion of nitric oxide in humans. An experimental and clinical study. Circ Res 1993;73:1121-1127.
17. Fontaine R, Kim M, Kieny S. Die chirurgische Bechandlung der peripheren durchblutungsstorungen. Helv Chir Acta 1954;21:499-509.
18. Ueki Y, Miyake S, Tominaga Y, Eguchi K. Increased nitric oxide levels in patients with rheumatoid arthritis. J Rheumatol 1996;23:230-236.
19. Braman RS, Hendrix SA. Nanogram nitrite and nitrate determination in environmental and biological materials by vanadium (III) reduction with chemiluminescence detection. Anal Chem 1989;61:2715-2718.
20. Furchgott RF, Zawadzki JV. The obligatory role of endothelial cells in the relaxations of the arterial smooth muscle by acetylcholine. Nature 1980;286:373-376.
21. Furchgott RF. The role of endothelium in the responses of vascular smooth muscle to drugs. Annu Rev Pharmacol Toxicol 1984;24:175-197.
22. Chin JH, Azhar S, Hoffman BB. Inactivation of endothelial derived relaxing factor by oxidized lipoproteins. J Clin Invest 1992;89:10-18.
23. Drexler H, Zeiher AM, Meinzer K, Just H. Correction of endothelial dysfuction in coronary microcirculation of hypercholesterolaemic patients by L-arginine. Lancet 1991; 338:1546-1550.
24. Yamamoto T. Effect of argatroban on flap survival length. Nippon Ika Daigaku Zasshi 1995;62:351-359 (in Japanese).
25. Soda T, Ogura K. A case of Fournier's gangrene with healing accelerated by argatroban. Hinyokika Kiyo 1996;42:981-982 (in Japanese).
26. Wennmalm A, Benthin G, Petersson AS. Dependence of the metabolism of nitric oxide (NO) in healthy human whole blood on the oxygenation of its red cell haemoglobin. Br J Pharmacol 1992;106:507-508.
27. Donaldson MC, Matthews ET, Hadjimichael J, Rickles FR. Markers of thrombotic activity in arterial disease. Arch Surg 1987;122:897-900.
28. Lowe GD. Blood rheology in arterial disease. Clin Sci 1986; 71:137-146.
29. Nash GB, Thomas PRS, Dormandy JA. Abnormal flow properties of white cells in patients with severe ischaemia of the leg. Br Med J 1988;296:1699-1701.
30. Lassila R, Pettonen S, Lepantalo M, Saarinen O, Kauhanen P, Manninen V. Severity of peripheral atherosclerosis is associated with fibrinogen and degradation of cross-linked fibrin. Atheroscler Thromb 1993;13:1738-1742.
31. Kosugi T, Masuda Y, Kinjoh K, Yamashita S, Sunagawa M, Nakamura M. Effect of argatroban on the formation of artificial thrombus on dogs. Int J Tissue React 1995;17:109-116.
32. Ueki Y, Nagata M, Miyake S, Tominaga Y. Effect of a selective thrombin inhibitor argatroban on the immune system in maintenance hemodialysis patients with arteriosclerosis obliterans. Rinshotokennkyu 1994;71:213-215 (in Japanese).
33. Kubes P, Suzuki M, Granger DN. Nitric oxide: An endogenous modulator of leukocyte adhesion. Proc Natl Acad Sci USA 1991;88:4651-4655.
34. Kruszyna R, Kruszyna H, Smith RP, Thron CD, Wilcox DE. Nitrite conversion to nitric oxide in red cells and its stabilization as a nitrosylated valency hybrid of hemoglobin. J Pharmacol Exp Ther 1987;241:307-313.
35. Stamler JS, Jia L, Eu JP, et al. Blood flow regulation by S-nitrosohemoglobin in the physiological oxygen gradient. Science 1997;276:2034-2037.